Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary
The DOI matches its Crossref record; 123 of the 130 references it cites were found in a registry or an index.
Abstract
The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a)…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence favors the need to assess apo Becontaining lipoproteins to account for remnant lipoproteins and small dense lipoproteins responsible for residual ASCVD risk not seen with a standard lipid panel of total cholesterol, LDL-C, and HDL-C.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [314]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175 · cited 14×
“adults, 112 mg/dL (3), is higher than the recommended LDL-C goal of <100 mg/dL for those with moderate ASCVD risk and well above the goals for people at high risk of ASCVD (1).”
InfluentialCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 6×
“Outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in which achieved LDL-C levels were substantially lower than those in statin trials further reinforced the notion that “lower is better” (24,25).”
InfluentialThe Health consequences of smoking—50 years of progress : a report of the Surgeon General
Lushniak, B. D., Samet, J. M., Pechacek, T. F., Norman, L., & Taylor, P. A. (2014) · Cited by 4,990
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Research works printed but not linked: 4
- Sever, 2003, J Am Coll Cardiol., 361, 1149
- Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Cardiovasc Diabetol., 366, 1849
- 2000, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease, N Engl J Med., 102, 21
- Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet., 376, 1670, 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
Cited by
Items 101–200 of 246
Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
Parhofer, K. G., Julius, U., Herzog, A. L., Krüger, T., Weinmann‐Menke, J., Heine, G. H., Cao, H., Schorr, J., Ferber, P. C., Wang, J., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag073 · Cited by 15
Management of Mild-to-Moderate Hypertriglyceridemia
Pulipati, V. P., Brinton, E. A., & Hatipoğlu, B. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.07.003 · Cited by 12
Self-citationValidation of the Hepamet fibrosis score in a multi-ethnic Asian population
Chong, S.-E., Chang, F. W. S., Chuah, K. H., Sthaneshwar, P., Mustapha, N. R. N., Mahadeva, S., & Chan, W. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100888 · Cited by 11
Dai, R., Zhao, X., Zhuo, H., Wang, W., Xu, Y., Hu, Z., Zhang, T., & Zhao, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1016126 · Cited by 10
“(A) TC, TG, HDL-C, and LDL-C; (B) LDL-C subfractions (LDLC-1 to LDLC-7) and sdLDL-C.”
BackgroundMethodInfluentialDu, Y., Yang, L., An, Y., Song, Y., & Lu, Y. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03489-9 · Cited by 9
Yang, N., Wang, M., Liu, J., Liu, J., Hao, Y., Zhao, D., & on behalf of CCC-ACS Investigators (2022) · Metabolites · doi:10.3390/metabo12100898 · Cited by 9
Lipoprotein(a) is a Prevalent yet Vastly Underrecognized Risk Factor for Cardiovascular Disease
Rendler, J., Murphy, M., & Yeang, C. (2024) · ASEAN Journal of Psychiatry · doi:10.54615/2231-7805.397 · Cited by 8
Manla, Y., AbdelWareth, L., Shantouf, R. S., Aljabery, Y., John, T. L. S., Sabbour, H. M., Piechowski‐Jóźwiak, B., & Almahmeed, W. A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1439013 · Cited by 8
Lipoprotein (a) in primary cardiovascular disease prevention is actionable today
Parcha, V., & Bittner, V. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100581 · Cited by 16
RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus
Saboo, B., Agarwal, S., Makkar, B. M., Chawla, R., Ghosh, S. K., Viswanathan, V., Gupta, S., Kumar, C. V., Maheshwari, A., Sreenivasamurthy, L., et al. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01063-6 · Cited by 11
de Carvalho, F. S., Marques, F. D. B., Lopes, A. E., Ferreira, J. L., & Príncipe, R. M. (2023) · Cureus · doi:10.7759/cureus.33509 · Cited by 11
“As such, mean LDLcholesterol level are unacceptable by current standards [6,12,13].”
BackgroundTemporal trends in lipoprotein(a) testing among United States veterans from 2014 to 2023
Gomez, S. E., Furst, A., Chen, T. P., Din, N., Maron, D. J., Heidenreich, P. A., Kalwani, N. M., Nallamshetty, S., Ward, J. H., Lozama, A., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100872 · Cited by 8
“Increasingly, practice guidelines recommend screening among those with a history of ASCVD [9], with more recent guidelines recommending one-time testing for all adults [10 – 12].”
BackgroundShi, J., Meng, M., Sa, R., Li-jun, Y., Lu, Y., & Gao, B. (2024) · Clinics · doi:10.1016/j.clinsp.2024.100379 · Cited by 7
The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder
Loh, W. J., & Watts, G. F. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01077-9 · Cited by 9
Real-world safety of icosapent ethyl: analysis based on spontaneous reports in FAERS database
Cai, H., Jia, B., Fu, Z., Chen, B., Liu, Y., & Zhao, S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2274946 · Cited by 7
“If the triglycerides of patient remain >150 mg/dL with the statin-IPE regimen, a fibrate or niacin may be considered [8].”
BackgroundBarrios, V., Escobar, C., Anguita, M. P., Esteban, V. I. A., Ruíz, R. C., Cosín-Sales, J., Cabello, M. I. E., Martínez, J. M. G., Guijarro, C., Mostaza, J. M., et al. (2021) · REC CardioClinics · doi:10.1016/j.rccl.2021.05.002 · Cited by 8
“26 However, these associations use a scale for stratifying CV risk that differs from the European scale, and consequently its application is difficult in our environment .”
BackgroundAhmad, W. A. W., Rosman, A., Bavanandan, S., Mohamed, M., Kader, M. A. S. A., Muthusamy, T. S., Cardiology, C. V. S., Lam, K. H., Kasim, S. S., Hoo, F. K., et al. (2023) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2023.30.1.6 · Cited by 9
Xu, J. Q., Zhu, L., Xie, Y., Zhang, M., Xiao, Z., Su, R., Wen, T., & Liu, L. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230328110215 · Cited by 6
A Jordanian Multidisciplinary Consensus Statement on the Management of Dyslipidemia
Mousa, E. A., Al-Azzam, S. I., Araydah, M., Karasneh, R. A., Ghnaimat, M. A., Al-Makhamreh, H. K., Khawaldeh, A., Al-Samen, M. A. A., HADDAD, J. A., Najjar, S. A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134312 · Cited by 9
“Adopted from the 2020 AACE/ACE consensus statement on the management of dyslipidemia [46].”
BackgroundMethodResearch Progress on the Pathogenesis and Treatment of Neoatherosclerosis
Guo, Y.-S., Yang, N., Wang, Z., & Wei, Y. (2024) · Current Medical Science · doi:10.1007/s11596-024-2915-x · Cited by 6
Evaluation of Lipoprotein Profile and Residual Risk Three Years After Bariatric Surgery
Arnáiz, E. G., Ballesteros-Pomar, M. D., Roza, L. G., de la Maza, B. P., Bachiller, B. R., Cobo, D. A., Fondo, A. U., & Rodríguez, I. C. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05543-2 · Cited by 7
“The American Association of Clinical Endocrinologists [32] considers non-HDL to be a more relevant CVR factor than LDL-c itself and establishes 5 risk categories and sets therapeutic targets for each of them.”
BackgroundPatti, G., Cavallari, I., Cesaro, A., Gragnano, F., Riva, L., Fimiani, F., Cuccia, C., Fresco, C., Calabrò, P., Leonardi, S., et al. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.107137 · Cited by 6
Fonseca, A. F., Byrne, H., Laguna-Fernández, A., Itani, T., Studer, R. L., Heo, J., Dillon, A., Ferber, P. C., & Costa‐Scharplatz, M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.519 · Cited by 7
Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes
Ma, G. S., Chiou, T. T., & Wilkinson, M. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01937-z · Cited by 5
“Finally, in patients with established CAVD, Lp(a) may help identify patients who may stand to benefit from more aggressive aortic valve surveillance, given the association of more rapid valve deterioration and need for replacement in those at the highest tertiles of Lp(a) levels [29, 37].”
BackgroundVideo-Based Respiration Rate Measurement With Adaptive Filtering and Quality-Guided Pulse Selection
Song, R., Zhao, W., Cheng, J., Li, C., & Yang, X. (2024) · IEEE Transactions on Instrumentation and Measurement · doi:10.1109/tim.2024.3413165 · Cited by 6
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.02.001 · Cited by 26
Concordance between LDL-C estimated by various formulas and directly measured LDL-C
David-Pardo, D. G., Ruiz, Á. J., Múñoz, Ó., Peña, Á. A. G., García, D. X. S., & Arcila, J. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.08.009 · Cited by 6
Romero-Ibarguengoitia, M. E., González‐Cantú, A., Hernández-Ruíz, Y. G., Armendariz-Vázquez, A. G., Rivera-Salinas, D., Montelongo-Cruz, L. P., Rio-Parra, G. F. D., Barco-Flores, I. A., González-Facio, R., & Sanz‐Sánchez, M. Á. (2022) · Vaccines · doi:10.3390/vaccines10030392 · Cited by 5
Barrios, V., Escobar, C., Anguita, M. P., Arrarte, V., Ruíz, R. C., Cosín-Sales, J., Cabello, M. I. E., Martínez, J. M. G., Guijarro, C., Mostaza, J. M., et al. (2021) · REC CardioClinics · doi:10.1016/j.rccl.2021.02.006 · Cited by 6
Wong, N. D. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.01.004 · Cited by 5
Padilla, F., Ruiz-Bernes, L. N., Román-Pintos, L. M., Peraza-Zaldívar, J. A., Sander-Padilla, J. G., Lugo‐Sánchez, L. A., RIOS-BRITO, K. F., Arguedas-Núñez, M. M., FLORES-HUANOSTA, D., & González‐Canudas, J. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00410-y · Cited by 6
“The advantage of this combination seems to be due to different mechanisms of action [3, 9–11].”
InfluentialAnanchaisarp, T., Chamroonkiadtikun, P., Bunchote, K., Thedpun, J., Srisamoot, C., Rujiworanat, C., Jayasakul, V., Chaiphom, N., Kittivarapong, T., Chuaysong, N., et al. (2025) · BMC Family Practice · doi:10.1186/s12875-025-03039-x · Cited by 4
“…as 10 years and ≥ 10 years), obesity, hypertension, triglycerides (categorized as 150 mg/dL and ≥ 150 mg/dL per established thresholds [26]), HDL cholesterol (categorized as low (defined as 40 mg/dL for men and 50 mg/dL for women) or high according to standard definitions [26]).”
Ancestral Variation in Lp(a): Epidemiology, Isoform Diversity, and Testing
Shah, P., King, S., Trabanino, S., Parsa, S., Chen, T. P., & Rodríguez, F. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01365-0 · Cited by 4
Metabolic disorders after traumatic brain injury: a narrative review of systemic consequences
Kursancew, A. C. S., Faller, C. J., Piva-Uchida, E. M., Benedet, I. B., Maciel, P. M., de Figueredo, S. M., Petronilho, F. C., Ceretta, L. B., STRECK, E. L., & Generoso, J. S. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-024-01524-3 · Cited by 5
“The main causal factors are family history, solid genetic prevalence, obesity, sedentary life-style, nutrition, and medication (Handelsman et al. 2020).”
Tada, H., Kojima, N., Yamagami, K., Takeji, Y., Sakata, K., Usui, S., Kawashiri, M., & Takamura, M. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.120 · Cited by 9
Impact of Statin Nonacceptance on Cardiovascular Outcomes in Patients With Diabetes
Shah, N. B., Lan, Z., Brown, C. J., Martin, S. S., & Turchin, A. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040464 · Cited by 5
Ebid, A. I. M., Genina, Y. M. F., Al-Jendy, A.-M. A., & El-Sawy, A. M. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0021 · Cited by 4
The prevalence of dyslipidemia in patients on hemodialysis: a cross-sectional study from Syria
Hasan, Y., Alsultan, M. K., Anan, M. T., Hassn, Q., & Basha, K. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000931 · Cited by 5
“Dyslipidemia of each lipids component is considered as follows: hyper-TC (≥200 mg/dl), hyper-TG (≥150 mg/dl), hyperLDL (≥100 mg/dl), hypo-HDL (< 40 mg/dl), hyper-Non-HDL (≥130 mg/dl)([14,15]).”
Long-term trends in lifestyle factors among respondents with dyslipidemia in the United States
Bai, B., Liu, Q., Liu, Y., Liu, F., Wang, Y., Chen, Y., Liang, Y., Wang, H., Wu, C., Guo, L.-Y., et al. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.06.025 · Cited by 9
Felix, B., Aldoohan, F., Kadirage, H. U., Sajeev, S. K., Kayani, M., Saeed, M. A. I. H., Vempatapu, S., Nasim, K., Pendem, H., Armenta, A. P., et al. (2024) · Cureus · doi:10.7759/cureus.65568 · Cited by 9
“The 2020 guidelines by the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE), as outlined by Handelsman et al. [78], focus on comprehensive dyslipidemia management and CVD prevention.”
BackgroundMoffatt, E. K., Wargo, R., Johnson, C., & Kawaguchi‐Suzuki, M. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1544 · Cited by 4
Gu, J., Sanchez, R. J., Chauhan, A., Fazio, S., & Rosenson, R. S. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.10.001 · Cited by 6
Self-citationRaju, K., Sharifa, A., Soumya, P., Khanam, R., & Bhargav, K. K. B. (2023) · Cellular Molecular and Biomedical Reports · doi:10.55705/cmbr.2022.361364.1064 · Cited by 4
Nabhani, I. A., Andrews, C. N., Sibai, J., Atenafu, E. G., Young, T., Chan, S. M., Gupta, V. K., Maze, D. C., Schimmer, A. D., Schuh, A. C., et al. (2022) · eJHaem · doi:10.1002/jha2.607 · Cited by 4
Marati, K., Palatheeya, S., Chettupalli, A. K., & Bukke, S. P. N. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00836-z · Cited by 5
Hernández-Jiménez, S. C., García-Ulloa, A. C., González-Flores, E., Hernández-Juárez, D., Alcántara-Garcés, M. T., Ramírez-Rodríguez, A. M., García-Padilla, C. E., Rull‐Gabayet, M., Landa-Anell, M. V., Melgarejo-Hernández, M. A., et al. (2022) · Alad · doi:10.24875/alad.22000018 · Cited by 5
Lao, M., Ou, Q., Shan, G., Zheng, M., Pei, G., Xu, Y., Wang, L., Tan, J., & Lü, B. (2023) · Respiratory Medicine · doi:10.1016/j.rmed.2023.107408 · Cited by 3
The Association of Niacin Use with Kidney Outcomes and Mortality
Takahashi, R., Bui, T.-A., Elali, I., Tran, D., Sumida, K., Thomas, F., Dukkipati, R. B., Shah, A. P., Rhee, C. M., Kovesdy, C. P., et al. (2025) · American Journal of Nephrology · doi:10.1159/000543098 · Cited by 4
“In addition, according to the AACE/ACE, niacin is a treatment option for patients with severe hypertriglyceridemia ( > 500 mg/ dL) to reduce the risk of acute pancreatitis [19].”
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention
Kamanu, C., & Karalis, D. G. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01283-1 · Cited by 6
“They have a larger effect on tri - glycerides with reductions of 25 to 35% in patients with high triglycerides (150 to 499 mg/dL) and even greater reduc - tions of up to 55% when triglycerides are severely elevated ( ≥ 500 mg/dL) [ 36 ].”
Evaluation of lipid-lowering therapy in patients with elevated lipoprotein(a) levels
Kelly, M. S., Jeminiwa, R. N., Gohar, F., Fanous, M., Ramirez, P., & Dixon, D. L. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.200 · Cited by 3
Li, Z., Wang, Q., Liu, Y., Wang, L., Yu, Z.-Q., Huang, Q., & Zhang, J. (2021) · Medical Science Monitor · doi:10.12659/msm.934471 · Cited by 3
“Each of the above factors was tested on a fully automated biochemical instrument, and the Friedewald formula was used to calculate LDL-C [8].”
MethodInfluentialAbu‐Alfa, A. K., Atallah, P., Azar, S. T., Dagher, E., Echtay, A. S., Amm, M., Hazkial, H. G., Kassab, R., Medlej, R., & Mohamad, M. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01340-x · Cited by 4
“[59] \ 100 mg/dL or\ 70 mg/dL if very high risk or\ 55 mg/dL if extreme risk”
BackgroundRole of LDL and Triglycerides in Hyperlipidemia in Diabetes Mellitus
Bethelli, S., & Oroszi, T. L. (2023) · Journal of Family Medicine and Disease Prevention · doi:10.23937/2469-5793/1510155 · Cited by 6
Najmi, E. A., Mirzaasgari, Z., Motamed, M. R., & Aslani, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314031 · Cited by 4
The role of icosapent ethyl in cardiovascular risk reduction
Goldenberg, R., CHENG, A. Y. Y., Gilbert, J. D., Lonn, E., Pedersen, S. D., & Verma, S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000873 · Cited by 3
“AACE Consensus Statement on Dyslipidemia 2020 [57] Patients with TG 135–499 m diabetes mellitus with at le”
BackgroundWardani, I. S. (2023) · Jurnal Penelitian Pendidikan IPA · doi:10.29303/jppipa.v9i9.5274 · Cited by 3
“Statins have an important role in preventing cardiovascular events related to atherosclerotic lesions and blood lipids (Handelsman, 2020).”
BackgroundLiu, G., & Zhu, X. (2024) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_6_24 · Cited by 2
Najafi, A., Moghtaderi, F., Seyedjafari, B., Rostampour, K., & Salehi‐Abargouei, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-00612-3 · Cited by 4
“It can be treated through changing dietary habits 96 .”
Lan, N. S. R., Ryan, C. D., Rudén, A., Glasby, J. R. K., Nanayakkara, N., Elghattis, Y., Brazionis, L., Huang, M., Lum, S., Januszewski, A. S., et al. (2025) · Internal Medicine Journal · doi:10.1111/imj.70276 · Cited by 3
Toward an Integrated Therapeutic Approach for Familial Hypercholesterolemia
Balkrishna, A., Agarwal, U., Saxena, S., Sharma, G., & Arya, V. (2026) · Current Medical Science · doi:10.1007/s11596-025-00149-6 · Cited by 2
“Statins function by diminishing the production of cholesterol in the liver through the inhibition of the enzyme HMG-CoA reductase, which is responsible for the synthesis of cholesterol precursors [27, 28].”
Lipoprotein(a) and Women’s Cardiovascular Health
Michos, E. D., Saucier, S. J., Mehran, R., & Koschinsky, M. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102744 · Cited by 4
ASCVD risk stratification using apolipoprotein B and the LDL-C to total cholesterol ratio
Wang, B., Nurmohamed, N. S., Kraaijenhof, J. M., & Li, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag260 · Cited by 4
Hubbard, D. M., McKinley, E., Colantonio, L. D., Poudel, B., Rosenson, R. S., Brown, T. M., Jackson, E. A., Huang, L., Orroth, K. K., Mues, K. E., et al. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100121 · Cited by 3
“The AACE/ACE statement also recommends a PCSK9i for patients with LDL-C ≥ 55 mg/dL with extremely high ASCVD risk despite maximally tolerated statin therapy and/or ezetimibe [7].”
BackgroundApolipoprotein B: An essential cholesterol metric for atherosclerotic cardiovascular disease
Fischer, K., & Kassem, L. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac287 · Cited by 3
Influence of Statins and Fibrates Drugs on Bone Health and Regeneration
Santiago, O., Ruggieri, I. N. C., Paulini, M. R., Fazan, V. P. S., Issa, J. P. M., & Feldman, S. (2024) · Journal of Biomaterials and Nanobiotechnology · doi:10.4236/jbnb.2024.151001 · Cited by 3
Frequency of lipoprotein(a) testing and its levels in Pakistani population
Batool, H., Khan, M., Ain, Q., Chughtai, O. R., Khan, M. D., Khan, M. I., & Sadiq, F. (2024) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2024.37 · Cited by 2
Clinical strategies for reducing cholesterol levels
Lardinois, C. K., & Karr, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00027-4 · Cited by 2
Amini, M. R., Sheikhhossein, F., Bazshahi, E., Rahimi, H., Ghalandari, H., Ghaedi, E., & Askarpour, M. (2023) · Journal of Nutritional Science · doi:10.1017/jns.2023.22 · Cited by 4
“We assigned low risk (L), some concerns (S) and high risk (H) of bias for each six items presented in Table 1, based on Cochrane Collaboration risk of bias tool((11)) and according to the following criteria: (1) randomisation process; (2) deviations from the intended interventions; (3) missing outcome data; (4) measur…”
BackgroundMethodInfluentialSelecting an Appropriate Animal Model for Dyslipidemia
Mallya, P., & Lewis, S. A. (2024) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.58.3s.72 · Cited by 2
Lin, L., Kiryakos, J., Ammous, F., Ratliff, S. M., Ware, E. B., Faul, J. D., Kardia, S. L. R., Zhao, W., Birditt, K. S., & Smith, J. A. (2024) · Research Square · doi:10.21203/rs.3.rs-3934965/v1 · Cited by 2
“Dyslipidemia, a major risk factor for CVD (2–4), is a modi�able condition characterized by decreased high-density lipoprotein-cholesterol (HDL-C), elevated low-density lipoprotein-cholesterol (LDL-C), and/or elevated triglycerides (TG) (5).”
BackgroundClinical Care of Lipids in People with Type 1 Diabetes
Lan, N. S. R., Jenkins, A. J., & Fegan, P. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_28 · Cited by 3
Evaluation of Vitamin D in Patients with Type 2 Diabetes Mellites
Ahmed, H. S., Hilal, N. N., & Zakari, M. G. (2023) · South Asian Research Journal of Pharmaceutical Sciences · doi:10.36346/sarjps.2023.v05i04.010 · Cited by 1
“These particles are more susceptible to arterial entrance and retention, oxidation, have a lower affinity for the LDL receptor, and are more likely to cause atherosclerosis [23].”
BackgroundGuidelines-disease-specific and context blind: a case of type 2 diabetes
Violante-Cumpa, J. R., Gonzalez‐Cruz, D., Rios-Ortega, A. G., González‐González, J. G., & Rodríguez‐Gutiérrez, R. (2023) · Medicina Universitaria · doi:10.24875/rmu.23000037 · Cited by 1
The Effects of Medium-Chain Triglyceride Oil and Butter on Lipid Profiles
Hoang, T. D., Hatfield, J. S., Nadolsky, K. Z., Bonsu, O., Nath, P. V., Tuamokumo, F. O., & Shakir, M. K. M. (2024) · Cureus · doi:10.7759/cureus.62556 · Cited by 2
“Therefore, reducing the levels of LDL, non-high-density lipoprotein (HDL), and ApoB is recommended based on individuals' ASCVD risk [11,12].”
BackgroundStatin Use in Women: Unique Aspects over the Lifespan
Myerson, M. L. (2024) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-024-00757-2 · Cited by 1
“While there are no PCOS-specific LDL-C goals, but it is reasonable to count PCOS as a risk factor in determining risk level [42 ].”
Dietary Patterns for Cardiometabolic Risk Reduction: Moving from Evidence to Implementation
Chiavaroli, L., Glenn, A. J., Kavanagh, M. E., Kendall, C. W. C., & Sievenpiper, J. L. (2025) · Springer eBooks · doi:10.1007/978-3-031-82888-1_8 · Cited by 1
Nutritional ketosis as therapeutic regimen for metabolic disorders: Perspectives and challenges
Ul‐Haq, I., Saleem, K., Iftikhar, H., & Abdi, G. (2025) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2025.101981 · Cited by 3
Maliha, M., Nazarenko, N., Nagraj, S., Satish, V., Kharawala, A., Borkowski, P., Garg, V., Saralidze, T., Karamanis, D., & Palaiodimos, L. (2025) · Heart Views · doi:10.4103/heartviews.heartviews_138_24 · Cited by 1
“18-21] In contrast, the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) consider levels above 30 mg/dL or 75 nmol/L to be elevated.”
Fenofibrate in managing cholestatic pruritus in paediatric patients
Quintero, J., Juampérez, J., Fornieles, C. P., Larrarte-King, M., Mameli, S., Vidal-Valdivia, L., Clemente, S., Fernández-Polo, A., Molino, J. A., & Mercadal‐Hally, M. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102132 · Cited by 2
Myerson, M. L., Warden, B. A., Saseen, J. J., & Paparodis, R. D. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.044134 · Cited by 2
Feng, S., Zou, S., Tang, M., Tian, R., & Xu, Y. (2025) · Vascular Health and Risk Management · doi:10.2147/vhrm.s553282 · Cited by 1
Expert Review of the Strategies to Optimize Long-Term Outcomes After Coronary Artery Bypass Grafting
Mokhtassi, S. S., Bulut, H., Salmasi, M. Y., & Khoshbin, E. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39887 · Cited by 3
Estándares SEA 2026 para el control global del riesgo vascular
Mostaza, J. M., Pintó, X., Armario, P., Guijarro, C., Masana, L., Real, J. T., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2026) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500889 · Cited by 2
Mohamed, D. A., Elbakry, H. F. H., Gamil, I., Abdelgayed, S. S., & Mabrok, H. B. (2026) · Applied Biosciences · doi:10.3390/applbiosci5010017 · Cited by 1
“Hyperlipidemia is a prevalent global metabolic disorder and a major contributor to cardiovascular disease (CVD) and stroke, accounting for approximately 2.6 million deaths annually and nearly 4.5% of worldwide mortality [1].”
InfluentialClinical Practice Guideline on the Pharmacological Management of Antipsychotic-Related Dyslipidemia
Carolan, A., Hynes, C., Bourke, R., Columb, D., Cullen, W., de Ferranti, S. D., Harrington, S. M., Kelleher, I., Kennedy, C., Khoury, M., et al. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag086 · Cited by 1
SEA 2022 standards for the comprehensive control of cardiovascular risk
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.06.002 · Cited by 12
Ponir, C., Seals, A. L., Caldarera, T., Ip, E. H., German, C. A., Taylor, Y. J., Moore, J. B., Bosworth, H. B., Shapiro, M. D., & Pokharel, Y. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad082 · Cited by 1
Consideraciones clínicas y estrategias terapéuticas para reducir el riesgo residual
Olmo, M. R. F., & Llergo, J. T. (2023) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(23)00011-0 · Cited by 2
Debunking the Myth: Eggs and Heart Disease
Haward, R., Chacko, J. S., Konjeti, S., Metri, G. R., Binoy, B. K., Haward, R., & Raju, S. (2024) · Cureus · doi:10.7759/cureus.59952 · Cited by 1
“Furthermore, assessing the isolated effects of egg yolks on cardiovascular health is complicated by dietary patterns and individual variations in cholesterol metabolism and genetic predispositions [57, 58].”
BackgroundManaging Medical Comorbidities in Clinical Practice
Grover, S. (2022) · Journal of Mental Health and Human Behaviour · doi:10.4103/jmhhb.jmhhb_155_22 · Cited by 1
Vilagut, F. T. (2021) · doi:10.52102/control_dislipemia/art-2
Methenitis, S. K., Papadopoulou, S. Κ., Panayiotou, G., Kaprara, A., Hatzitolios, A. I., Skepastianos, P., Karali, K., & Feidantsis, K. G. (2023) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2023.01.003 · Cited by 1
Kheir, O. O., Dossary, S., Dhalaan, M., AlHajri, S., Aljeshi, A., Dawoud, R. W., & Ghamdi, M. (2024) · Qeios · doi:10.32388/t52nt9.5 · Cited by 1
Xu, J., Du, X., Zhang, S., Xiang, Q., Guo, L., Zhu, L., Tan, Y., Fu, Y., Xie, Y., Zhang, M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-871652/v1
Pérez, A., de Victoria, E. O. M., Arrieta, F., Caixàs, A., Mazo, E. S., Fernández-Catalina, P., Martínez‐Hervás, S., Medina, J. A., Suárez-Gutiérrez, L., Planelles, J. R. U., et al. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.07.009
Chen, D., Feng, H., Li, Y., & Huang, J. (2021) · Research Square · doi:10.21203/rs.3.rs-1037189/v1
Moreno-Fernández, J., Sastre, J., Pinés, P. J., Zaballos, F. D. V., Calderón-Vicente, D., Quiroga, I., Herránz, S., Gallardo, G. L., Gonzalez, J., & Muñoz‐Rodríguez, J. R. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109221
DEFINIÇÃO, CLASSIFICAÇÃO, DIAGNÓSTICO E TRATAMENTO DE DM1
Costa, A. M. D. C., Altino, M. P., Johannesson, A. L. R., Filho, J. V. D. S., Braga, I. R. C., & Vasconcelos, I. T. G. F. (2022) · Amplla Editora eBooks · doi:10.51859/amplla.ecc136.1122-1
Maia, F. P. A., Muniz, F. M., Sobreira, D. T. P., Filho, R. E. P. C., Portela, A. L., & Quidute, A. R. P. (2022) · Amplla Editora eBooks · doi:10.51859/amplla.ecc136.1122-10
Metadata
- Authors
- Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., Garber, A. J., Grunberger, G., Krauss, R. M., Mechanick, J. I., Rosenblit, P. D., Smith, D. A., & Wyne, K. L.
- Affiliations
- University of Miami (US)
- University of California San Diego (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of California, Los Angeles (US)
- University of Chicago (US)
- Oregon Health & Science University (US)
- Tulane University (US)
- Baylor College of Medicine (US)
- Oakland University (US)
- University of California, San Francisco (US)
- University of California, Irvine (US)
- The Ohio State University Wexner Medical Center (US)
- Corresponding author
- Handelsman, Yehuda
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 26
- Issue
- 10
- Pages
- 1196-1224
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3095590613
- Cited by
- 248
- References
- 130
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 58 · 2023: 50 · 2022: 57 · 2021: 26 · 2020: 1
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- dyslipidemia management, atherosclerotic cardiovascular disease prevention, LDL cholesterol targets, high-intensity statin therapy, PCSK9 inhibitors, ezetimibe, colesevelam, bempedoic acid, triglyceride-lowering therapy, fibrates, omega-3 fatty acids, nicotinic acid, icosapent ethyl, lipoprotein(a), statin intolerance, lifestyle therapy, cardiovascular risk stratification
- MeSH terms
- Endocrinologists, Algorithms, Anticholesteremic Agents, Cardiovascular Diseases, Humans, Risk Factors, United States, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Consensus, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.